Related Experiment Video

Updated: Jan 22, 2026

Robotic Production of Cancer Cell Spheroids with an Aqueous Two-phase System for Drug Testing
09:58

Robotic Production of Cancer Cell Spheroids with an Aqueous Two-phase System for Drug Testing

Published on: April 23, 2015

9.4K

Challenges of the phase I drug development in non-small cell lung cancer

Chia-Chi Lin1

  • 1Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. cclin1@ntu.edu.tw.

Chinese Clinical Oncology
|July 18, 2019
PubMed

Insights

This article discusses phase 1 lung cancer drug development strategies, focusing on precise dosing, biomarker patient selection, and early efficacy assessments for personalized treatments.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Phase 1 clinical trials are critical for early-stage drug development.
  • Lung cancer drug development faces unique challenges in early phases.
  • Optimizing trial design is essential for successful therapeutic advancement.

Purpose of the Study:

  • To outline current challenges in phase 1 lung cancer drug development.
  • To present effective strategies for improving early-phase trial outcomes.
  • To discuss the evolving landscape of lung cancer drug research.

Main Methods:

  • Utilizing statistical modeling for precise dose determination.
  • Employing genetic or molecular biomarkers for enhanced patient selection.
  • Conducting pharmacokinetic and pharmacodynamic analyses.
  • Performing early evaluations of drug efficacy.

Main Results:

  • Biomarker-guided patient selection improves trial precision.
  • Molecular tumor profiling enables personalized therapeutic strategies.
  • Statistical modeling enhances dose-finding accuracy.
  • Early efficacy assessment informs further development.

Conclusions:

  • Phase 1 trials are increasingly incorporating personalized medicine approaches.
  • Multi-institutional collaboration and centralized management are becoming standard.
  • Optimized strategies enhance the efficiency and success rate of lung cancer drug development.
Keywords:
Lung cancermolecular profilingphase 1 development

More Related Videos

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

1.8K
Three-Dimensional Phase Resolved Functional Lung Magnetic Resonance Imaging10:44

Three-Dimensional Phase Resolved Functional Lung Magnetic Resonance Imaging

Published on: June 21, 2024

1.1K

Related Concept Videos

Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
4.7K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.3K
Phase Diagrams02:39

Phase Diagrams

A phase diagram combines plots of pressure versus temperature for the liquid-gas, solid-liquid, and solid-gas phase-transition equilibria of a substance. These diagrams indicate the physical states that exist under specific conditions of pressure and temperature and also provide the pressure dependence of the phase-transition temperatures (melting points, sublimation points, boiling points). Regions or areas labeled solid, liquid, and gas represent single phases, while lines or curves represent...
49.2K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K
Phase Transitions02:31

Phase Transitions

Whether solid, liquid, or gas, a substance's state depends on the order and arrangement of its particles (atoms, molecules, or ions). Particles in the solid pack closely together, generally in a pattern. The particles vibrate about their fixed positions but do not move or squeeze past their neighbors. In liquids, although the particles are closely spaced, they are randomly arranged. The position of the particles are not fixed—that is, they are free to move past their neighbors to...
22.8K